Dermatologic Adverse Events Associated with use of Adjuvant Lapatinib in Combination with Paclitaxel and Trastuzumab for HER2 positive Breast Cancer: A Case Series Analysis

Gelijkaardige items

• Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
  door: Tolaney, Sara M., et al.
  Gepubliceerd in: (2015)
• A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
  door: Iyengar, Neil M., et al.
  Gepubliceerd in: (2015)
• RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
  door: Moreno-Aspitia, Alvaro, et al.
  Gepubliceerd in: (2013)
• Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer
  door: Dang, Chau, et al.
  Gepubliceerd in: (2016)
• Dermatological adverse events with taxane chemotherapy
  door: Sibaud, Vincent, et al.
  Gepubliceerd in: (2016)